ALCAM and adenocarcinoma: More recently, Zhang and coworkers reported that the selection of CD166+ cells from primary NSCLC, pertaining to adenocarcinomas or squamous cell carcinomas or luminal cell cancers, gives rise to an enrichment of about 100-fold in cells endowed with tumor-initiating capacities, while CD166− cells were unable to generate lung tumors when inoculated into immunodeficient mice [174].